Interestingly, circulating IL-37 expression is highest for ER+/PR+/HER2+ breast cancer patients, compared to PR+ breast cancer, but not ER+/PR+ breast patients without metastasis (57), suggesting that IL-37 may also influence the prognosis via ER+/PR+/HER2+ signalling. This evidence concerns the gene IL37 and breast carcinoma.